PharmaBoardroom

In an exclusive interview, Jean-Paul Clozel explains Idorsia's unique value proposition as a biotech focused on small molecules, how agnosticism in…

Japanese medtech player Terumo’s APAC lead Probir Das outlines the company’s 100-year commitment to innovation, its aggressive globalisation…

While many parts of the world ground to a halt as they tried to deal with the global pandemic, China had more or less brought the situation under…

Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare success story. CEO Dan Schneider…

Following the recent news of Remegen's massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to…

Roche Diagnostics Norway’s Daniel Malarek discusses the resurgence of diagnostics in the wake of the COVID-19 pandemic, the Norwegian approval…

Filip Standaert outlines the significance of the Nordic cluster to J&J’s medical device operations in Europe, how the affiliate responded to the…

Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine,…

Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what…

In a recent article for PharmaBoardroom, Objective Capital's David Crean took a look at the state of US innovation today and its long term…

The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from…

PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical…